Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

Uffe Høgh Olesen; Jakob Gramstrup Petersen; Antje Garten; Wieland Kiess; Jun Yoshino; Shin-Ichiro Imai; Mette Knak Christensen; Peter Fristrup; Annemette Vinding Thougaard; Fredrik Björkling; Peter Buhl Jensen; Søren Jensby Nielsen; Maxwell Sehested

doi:10.1186/1471-2407-10-677

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

Uffe Høgh Olesen, Jakob Gramstrup Petersen, Antje Garten, Wieland Kiess, Jun Yoshino, Shin-Ichiro Imai, Mette Knak Christensen, Peter Fristrup, Annemette Vinding Thougaard, Fredrik Björkling, Peter Buhl Jensen, Søren Jensby Nielsen, Maxwell Sehested

Research output: Contribution to journal › Journal article › Research › peer-review

44 Citations (Scopus)

Abstract

Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.

Original language	English
Journal	BMC Cancer
Volume	10
Pages (from-to)	677
Number of pages	13
ISSN	1471-2407
DOIs	https://doi.org/10.1186/1471-2407-10-677
Publication status	Published - 10 Dec 2010

Keywords

Faculty of Health and Medical Sciences

Access to Document

10.1186/1471-2407-10-677

http://www.biomedcentral.com/1471-2407/10/677

Cite this

Olesen, U. H., Petersen, J. G., Garten, A., Kiess, W., Yoshino, J., Imai, S-I., Christensen, M. K., Fristrup, P., Thougaard, A. V., Björkling, F., Jensen, P. B., Nielsen, S. J., & Sehested, M. (2010). Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. BMC Cancer, 10, 677. https://doi.org/10.1186/1471-2407-10-677

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. / Olesen, Uffe Høgh; Petersen, Jakob Gramstrup; Garten, Antje; Kiess, Wieland; Yoshino, Jun; Imai, Shin-Ichiro; Christensen, Mette Knak; Fristrup, Peter; Thougaard, Annemette Vinding; Björkling, Fredrik; Jensen, Peter Buhl; Nielsen, Søren Jensby; Sehested, Maxwell.

In: BMC Cancer, Vol. 10, 10.12.2010, p. 677.

Research output: Contribution to journal › Journal article › Research › peer-review

Olesen, UH, Petersen, JG, Garten, A, Kiess, W, Yoshino, J, Imai, S-I, Christensen, MK, Fristrup, P, Thougaard, AV, Björkling, F, Jensen, PB, Nielsen, SJ & Sehested, M 2010, 'Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase', BMC Cancer, vol. 10, pp. 677. https://doi.org/10.1186/1471-2407-10-677

Olesen, Uffe Høgh ; Petersen, Jakob Gramstrup ; Garten, Antje ; Kiess, Wieland ; Yoshino, Jun ; Imai, Shin-Ichiro ; Christensen, Mette Knak ; Fristrup, Peter ; Thougaard, Annemette Vinding ; Björkling, Fredrik ; Jensen, Peter Buhl ; Nielsen, Søren Jensby ; Sehested, Maxwell. / Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. In: BMC Cancer. 2010 ; Vol. 10. pp. 677.

@article{508a791fb1a24346bfbedea6a2f83a9a,

title = "Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase",

abstract = "Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.",

keywords = "Faculty of Health and Medical Sciences",

author = "Olesen, {Uffe H{\o}gh} and Petersen, {Jakob Gramstrup} and Antje Garten and Wieland Kiess and Jun Yoshino and Shin-Ichiro Imai and Christensen, {Mette Knak} and Peter Fristrup and Thougaard, {Annemette Vinding} and Fredrik Bj{\"o}rkling and Jensen, {Peter Buhl} and Nielsen, {S{\o}ren Jensby} and Maxwell Sehested",

year = "2010",

month = dec,

day = "10",

doi = "10.1186/1471-2407-10-677",

language = "English",

volume = "10",

pages = "677",

journal = "B M C Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

AU - Olesen, Uffe Høgh

AU - Petersen, Jakob Gramstrup

AU - Garten, Antje

AU - Kiess, Wieland

AU - Yoshino, Jun

AU - Imai, Shin-Ichiro

AU - Christensen, Mette Knak

AU - Fristrup, Peter

AU - Thougaard, Annemette Vinding

AU - Björkling, Fredrik

AU - Jensen, Peter Buhl

AU - Nielsen, Søren Jensby

AU - Sehested, Maxwell

PY - 2010/12/10

Y1 - 2010/12/10

N2 - Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.

AB - Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.

KW - Faculty of Health and Medical Sciences

U2 - 10.1186/1471-2407-10-677

DO - 10.1186/1471-2407-10-677

M3 - Journal article

C2 - 21144000

VL - 10

SP - 677

JO - B M C Cancer

JF - B M C Cancer

SN - 1471-2407

ER -